Company Name MyoKardia
Mailing Address 333 Allerton Ave. South San Francisco, CA 94080 USA
Company Description MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company’s first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
Proceeds Purposes Proceeds from the financing will be used to advance and expand the company’s portfolio of potential therapies for hypertrophic and dilated cardiomyopathies (HCM and DCM), including its lead drug candidate, MYK-461, which is currently in Phase 1 clinical trials.